Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4 CAD | +10.50% | +1.27% | +1.27% |
Mar. 14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 | |
Mar. 14 | HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.27% | 85.03M | |
+15.96% | 70.86B | |
+11.01% | 27.37B | |
-1.96% | 8.14B | |
+1.91% | 7.92B | |
-25.90% | 7.51B | |
+1.40% | 4.65B | |
+3.37% | 4.12B | |
+13.69% | 4.08B | |
-3.52% | 3.92B |
- Stock
- Equities
- Stock HLS Therapeutics Inc. - Toronto S.E.
- News HLS Therapeutics Inc.
- HLS Therapeutics Brief: Announcing that Vascepa Now Reimbursed by the Saskatchewan Drug Plan